YMAB vs. SLN, COGT, EOLS, BCYC, DNTH, IRON, PHAR, NRIX, SVRA, and AVTE
Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Silence Therapeutics (SLN), Cogent Biosciences (COGT), Evolus (EOLS), Bicycle Therapeutics (BCYC), Dianthus Therapeutics (DNTH), Disc Medicine (IRON), Pharming Group (PHAR), Nurix Therapeutics (NRIX), Savara (SVRA), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical preparations" industry.
Y-mAbs Therapeutics (NASDAQ:YMAB) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Y-mAbs Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
Y-mAbs Therapeutics has higher revenue and earnings than Silence Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.
Y-mAbs Therapeutics has a net margin of -25.26% compared to Silence Therapeutics' net margin of -171.41%. Y-mAbs Therapeutics' return on equity of -20.72% beat Silence Therapeutics' return on equity.
Y-mAbs Therapeutics presently has a consensus target price of $16.57, suggesting a potential upside of 12.65%. Silence Therapeutics has a consensus target price of $57.25, suggesting a potential upside of 164.98%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Y-mAbs Therapeutics.
Y-mAbs Therapeutics received 97 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Silence Therapeutics an outperform vote while only 60.51% of users gave Y-mAbs Therapeutics an outperform vote.
70.9% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 21.5% of Y-mAbs Therapeutics shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Y-mAbs Therapeutics and Y-mAbs Therapeutics both had 3 articles in the media. Y-mAbs Therapeutics' average media sentiment score of 0.53 beat Silence Therapeutics' score of -0.05 indicating that Y-mAbs Therapeutics is being referred to more favorably in the media.
Summary
Y-mAbs Therapeutics beats Silence Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Y-mAbs Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Y-mAbs Therapeutics Competitors List
Related Companies and Tools
